Laurus Labs' share price up 6% after blockbuster Q1 results

Laurus Labs is on a tear. The pharma stock jumped 6 per cent today, touching a new 52-week high of Rs 901 before settling at Rs 885. That’s nearly double what it was a year ago. The trigger? A knockout Q1 result, plus a generous land allotment from the Andhra Pradesh government. But here’s the rub: At nearly 95 times earnings, the stock is priced for perfection. Can Laurus deliver? Q1 FY26 results at a glance The company’s Q1 FY26 numbers impressed across the board—profits, margins, and revenue all moved up smartly. Add to that a land parcel of 532 acres in Andhra Pradesh for its ambitious Laurus Pharma Zone project, and investors are seeing a long growth runway ahead. Here’s how the Q1 numbers stack up: Metric Q1 FY26 Q1 FY25 YoY change Revenue Rs 1,570 crore Rs 1,198 crore 31 per cent EBITDA Rs 38